Sapient Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Sapient Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-325	Closed	-$251K	–	464
2026 Q1	$251K	Buy	+325	New	+$249K	﹤0.01%	396

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sapient Capital's REGN Position: Q2 2026 in Review

Sapient Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 325 shares — an estimated $251K sold.

Sapient Capital first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $251K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Sapient Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sapient Capital sold 325 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $251K.
Sapient Capital first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Sapient Capital's Regeneron Pharmaceuticals position peaked at $251K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.